CiVi Biopharma
Manufacturing · Pennsylvania, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1 Town Pl Ste 200, Bryn Mawr, Pennsylvan...Phone Number
(301) 968-2390Website
www.civibio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About CiVi Biopharma
CiVi Biopharma is focused on developing novel oral antisense oligonucleotide therapies. Their product pipeline includes CiVi 030, an intravenous formulation of iloprost for treating severe frostbite, and CiVi 008, a third generation PCSK9 antisense molecule aimed at treating hypercholesterolemia and preventing atherosclerotic cardiovascular disease. The company targets healthcare providers and patients in need of innovative treatments for serious medical conditions. With ongoing clinical and pre-clinical programs, CiVi Biopharma is committed to advancing its therapeutic offerings.Explore more
CiVi Biopharma Org Chart
CS
Chief Development Officer
JG
Financial Controller
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is CiVi Biopharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if CiVi Biopharma has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if CiVi Biopharma had a recent Job posting/layoffs
Product Launch: Get notified when CiVi Biopharma launches new products
Website visits: Recent activity has been detected on your website
Check out if CiVi Biopharma is spiking on competitors!
CiVi Biopharma, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on CiVi Biopharma recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at CiVi Biopharma
Funding: Get notified immidiatlly once CiVi Biopharma has new funding data
Recommended Actions
Find VP level buyers at CiVi Biopharma
Find 2 more new buyers
Compare Similar Companies to CiVi Biopharma
Compare insights from companies similar to CiVi Biopharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
CiVi Biopharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
CiVi Biopharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about CiVi Biopharma.
CiVi Biopharma Tech Stack
A closer look at the technologies used by CiVi Biopharma
CiVi Biopharma News & Media
CiVi Biopharma Resumes AURORA Phase 3 Clinical Trial of CIVI030 to Treat Systemic Sclerosis
CHEVY CHASE, Md., Oct. 1, 2020 /PRNewswire/ -- CiVi Biopharma, Inc., ("CiVi" or "the Company"), a privately held company focused on creating novel therapies against diseases where the unmet medical need exists, today announces that the Company, through its wholly-owned subsidiary, Eicos...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding CiVi Biopharma
Sign Up For FreeTo access detailed company insights
CiVi Biopharma is focused on developing novel oral antisense oligonucleotide therapies. Their product pipeline includes CiVi 030, an intravenous formulation of iloprost for treating severe frostbite, and CiVi 008, a third generation PCSK9 antisense molecule aimed at treating hypercholesterolemia and preventing atherosclerotic cardiovascular disease... Read More
